Benefits of using Richmond Pharmacology
Short start-up times of 4-6 weeks, rapid data readout
Exceptional ECG generation facilitating ECG over reading
Established relationships with regulatory agencies in EU, USA and Japan.
Experts in cardiac safety with state-of-the-art equipment
Low data variability allowing for smaller sample sizes
Thorough and intensive QTc Studies
Our experience in conducting QTc studies spans two decades and we are proud of our track record of 100% success. This demonstrated in our published studies.
We provide consultancy and expert reports in cardiac safety, the clinical conduct of intensive ECG studies, core laboratory services such as adjudication and the cardiology over reading of automated interval measurements. Our clinical staff specialise in statistical analysis concentration effect modelling, reporting, and publishing.
We provide sponsors with FDA compliant state of the art analysis methods, and the option to include a non-pharmacological method of proving assay sensitivity. Our unique and innovative approach means that we conduct our studies and prove assay sensitivity as a standard feature. This has provided quality data in many Japanese bridging, SAD and MAD studies eliminating the need for a dedicated TQT study.
Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.
Our core lab is situated at our clinical unit at London Bridge, offering a focused work environment with no additional costs, thereby delivering value for money to pharmaceutical sponsors.
We are a leading publisher in this area and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.